Beroni Group Limited

NSX:BTG ISIN:AU000000BTG8

Beroni GroupBeroni Group (NSX:BTG) (OTCMKTS:BNIGF) is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of a US FDA approved virus diagnostic kit, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. To learn more about Beroni, please visit www.beronigroup.com.

  

News

Beroni Group Limited (NSX:BTG) Receives COVID-19 Test Kits Commercial Order

🕔9/8/2020 11:21:00 AM 1201

Beroni Group (OTCQX:BNIGF) (NSX:BTG) today announced that it received the first commercial order for its proprietarily developed SARS-CoV-2 Antibody Detection Kit from Forsitech Inc., a pharmaceutical trading company based in Japan.

Read Full Article

Beroni Group Limited (NSX:BTG) Signs Agreement with Genscript Biotech

🕔8/12/2020 2:10:00 PM 1158

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) is pleased to announce that further to its announcement on August 4, 2020 regarding the development of a medical solution utilizing nanobody technology for COVID-19, it has just signed an agreement with GenScript Biotech Corporation

Read Full Article

Beroni Group Limited (NSX:BTG) Constructed Nanobodies for Coronavirus

🕔8/4/2020 2:30:00 PM 1054

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) today announced its further progress on the development of a medical solution using nanobody technology for the COVID-19 coronavirus in collaboration with Tianjin University in China.

Read Full Article

Beroni Group Limited (NSX:BTG) Beroni to Supply COVID-19 Antibody Test Kit to Japan

🕔7/10/2020 3:00:00 PM 1082

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) is pleased to announce that it is collaborating with Forsitech Inc. and Standard Capital Co., Ltd to supply its SARS-CoV-2 total antibody detection kit for clinical testing in the Japanese market.

Read Full Article

Beroni Group Limited (NSX:BTG) Dr Richard Buchta Appointed as Director

🕔6/30/2020 11:37:00 AM 1282

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) is pleased to announce that it has appointed Dr. Richard Buchta as an independent non-executive director of the Company

Read Full Article

Beroni Group Limited (NSX:BTG) Issue of shares

🕔6/23/2020 7:14:00 AM 1546

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) is pleased to announce that, the Company has completed the issue of 2,390,000 fully paid ordinary shares to the Directors, employees and scientists.

Read Full Article

Beroni Group Limited (NSX:BTG) Issue of US$2.97m Convertible Notes to Fund Growth

🕔6/9/2020 1:07:00 PM 1216

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG), an international diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, is pleased to announce that it has raised US$2.97 million via the issue of convertible notes to professional and sophisticated investors in Japan.

Read Full Article
###

2,456 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 21) (Last 30 Days: 436) (Since Published: 2456) 

Company Data

    Headquarters
  • Suite 401, 447 Kent Street
    Sydney, NSW 2000
    Australia
  • Telephone
  • +61 2 8051 3055 
  • Principal Sector
  • Biotech 
  • Principal Industry
  • Pharmaceutical 
  • Homepage
  • www.beronigroup.com

Social Media